| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $413K | -18.2% | +26.7% |
| SG&A Expense | $282K | -2.4% | -11.6% |
| Operating Income | -$1.2M | +40.2% | +78.7% |
| Net Income | -$1.1M | +41.2% | +79.9% |
| EPS (Basic) | -$0.04 | +42.9% | +81.0% |
| EPS (Diluted) | -$0.04 | +42.9% | +81.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.2M | -8.0% | +144.9% |
| Current Assets | $9.3M | -8.2% | +134.3% |
| Total Assets | $13.3M | -5.5% | +122.8% |
| Current Liabilities | $1.5M | +0.2% | -20.3% |
| Total Liabilities | $1.5M | -0.9% | -18.1% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.6M | — | — |
| Investing Cash Flow | -$345K | — | — |
| Financing Cash Flow | $9.6M | — | — |
| $11.8M |
| -6.1% |
| +185.1% |